Acadia Pharmaceuticals Inc

NASDAQ:ACAD  
21.17
-0.32 (-1.51%)
Products, Regulatory, Earnings Announcements

ACADIA Pharmaceuticals Announces Positive Top-Line Results From Pivotal Phase 3 Lavender Trial Of Trofinetide In Rett Syndrome

Published: 12/06/2021 21:15 GMT
Acadia Pharmaceuticals Inc (ACAD) - Acadia Pharmaceuticals Announces Positive Top-line Results From Pivotal Phase 3 Lavender Trial of Trofinetide in Rett Syndrome.
Acadia Pharmaceuticals Inc - is Preparing for a Pre-nda Meeting With U.S. Food and Drug Administration in Q1 of 2022.
Acadia Pharmaceuticals Inc - Plans to Submit a New Drug Application Around Mid-year 2022 for Trofinetide.
Revenue is expected to be $135.38 Million
Adjusted EPS is expected to be -$0.24

Next Quarter Revenue Guidance is expected to be $128.36 Million
Next Quarter EPS Guidance is expected to be -$0.25

More details on our Analysts Page.